Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2016', provides an overview of the Thrombocythaemia Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombocythaemia Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocythaemia Myelofibrosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis - The report reviews pipeline therapeutics for Thrombocythaemia Myelofibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Thrombocythaemia Myelofibrosis therapeutics and enlists all their major and minor projects - The report assesses Thrombocythaemia Myelofibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Thrombocythaemia Myelofibrosis Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Thrombocythaemia Myelofibrosis Overview 6 Therapeutics Development 7 Pipeline Products for Thrombocythaemia Myelofibrosis - Overview 7 Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies 8 Thrombocythaemia Myelofibrosis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Thrombocythaemia Myelofibrosis - Products under Development by Companies 11 Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development 12 Celgene Corporation 12 Gilead Sciences, Inc. 13 Incyte Corporation 14 JW Pharmaceutical Corporation 15 MEI Pharma, Inc. 16 Nippon Shinyaku Co., Ltd. 17 Novartis AG 18 Pfizer Inc. 19 Thrombocythaemia Myelofibrosis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 28 buparlisib hydrochloride - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CWP-291 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 glasdegib - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 INCB-39110 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 momelotinib dihydrochloride - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 NS-018 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 pomalidomide - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 pracinostat - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Thrombocythaemia Myelofibrosis - Recent Pipeline Updates 48 Thrombocythaemia Myelofibrosis - Dormant Projects 62 Thrombocythaemia Myelofibrosis - Discontinued Products 63 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Number of Products under Development for Thrombocythaemia Myelofibrosis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Thrombocythaemia Myelofibrosis - Pipeline by Celgene Corporation, H1 2016 12 Thrombocythaemia Myelofibrosis - Pipeline by Gilead Sciences, Inc., H1 2016 13 Thrombocythaemia Myelofibrosis - Pipeline by Incyte Corporation, H1 2016 14 Thrombocythaemia Myelofibrosis - Pipeline by JW Pharmaceutical Corporation, H1 2016 15 Thrombocythaemia Myelofibrosis - Pipeline by MEI Pharma, Inc., H1 2016 16 Thrombocythaemia Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 17 Thrombocythaemia Myelofibrosis - Pipeline by Novartis AG, H1 2016 18 Thrombocythaemia Myelofibrosis - Pipeline by Pfizer Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 27 Thrombocythaemia Myelofibrosis Therapeutics - Recent Pipeline Updates, H1 2016 48 Thrombocythaemia Myelofibrosis - Dormant Projects, H1 2016 62 Thrombocythaemia Myelofibrosis - Discontinued Products, H1 2016 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.